Leukemia & Lymphoma最新文献

{"title":"Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.","authors":"Marcel von Lucadou, Lea-Corinna Burbaum, Melanie Märklin, Jonas S Heitmann, Susanne Jung","doi":"10.1080/10428194.2026.2707891","DOIUrl":"https://doi.org/10.1080/10428194.2026.2707891","url":null,"abstract":"<p><p>Soluble immune mediators, such as checkpoint and cytokine receptors and their ligands, are emerging as biomarkers and potential therapeutic targets in hematologic malignancies. We assessed pretreatment levels of soluble PD-L1 (sPD-L1) as a prognostic biomarker in a retrospective single-center cohort of 54 newly diagnosed acute myeloid leukemia (AML) patients. Higher sPD-L1 levels were significantly associated with a greater disease burden and with patients undergoing allogeneic transplantation. Interpretation of longitudinal sPD-L1 data suggests that marked declines may reflect treatment response, whereas persistently high levels may indicate ongoing disease activity. In non-transplanted patients, high sPD-L1 levels were independently associated with inferior overall survival. These results indicate that sPD-L1 may inherently reflect high-risk characteristics that could potentially help guide treatment decisions.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study.","authors":"Bradley Uyemura, Fauzia Hollnagel, Aric Hall, Mathew Brunner, Zhubin Gahvari, Ryan J Mattison, Hongtao Liu, Michael J Fallon, Kalyan V Nadiminti","doi":"10.1080/10428194.2026.2711591","DOIUrl":"https://doi.org/10.1080/10428194.2026.2711591","url":null,"abstract":"<p><p>Biological markers such as disease risk and mutation profile can predict survival outcomes of acute myeloid leukemia (AML) treated with first-line venetoclax (Ven) in combination with a hypomethylating agent. However, the impact of socioeconomic factors with this regimen is unclear. Using a widely validated metric of disadvantage, Area Deprivation Index (ADI), we investigated the influence of socioeconomic disparity on overall survival (OS) in seventy-nine newly diagnosed patients with AML who received Ven-based therapy at the University of Wisconsin. Median OS was 6.77 months (IQR 2.52-11.57) with a cumulative mortality rate of 75.9%. While previous reports demonstrated worse outcomes in disadvantaged patients treated with intensive therapy, we observed no statistically significant difference between State/National ADI and OS (<i>p</i> = 0.697 and <i>p</i> = 0.582 respectively) in our Ven cohort.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies.","authors":"Danny Trotier, Manlu Liu, Arun Augustine, Kiruba Vembu, Meaghan Trainor, Priyanka Pophali","doi":"10.1080/10428194.2026.2715204","DOIUrl":"https://doi.org/10.1080/10428194.2026.2715204","url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell therapy (CART) has changed treatment for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but most patients still die of their disease and may benefit from palliative care (PC) or hospice services. Whether CART availability has affected PC or hospice referral patterns and end-of-life outcomes remains unclear. We conducted a single-center retrospective study for deceased patients with r/r DLBCL to evaluate PC and hospice utilization before and after CART introduction (87 pre-CART, 95 post-CART). PC referral rates were similar between eras (57.5% vs 70.5%, <i>p</i> = 0.39), as were hospice referrals (79.3% vs 83.2%, <i>p</i> = 0.78). However, patients in the post-CART era had shorter time from last treatment to death (95 vs 51 days, <i>p</i> = 0.001), higher hospitalization rates in the last 30 days of life (57.5% vs 72.6%, <i>p</i> = 0.03), and more in-hospital deaths (19.5% vs 33.7%, <i>p</i> = 0.045). Overall, 20-30% of patients were never referred to PC or hospice.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of O-GlcNAc glycosylated modified transferase on prognosis of diffuse large B-cell lymphoma and analysis of downstream targets.","authors":"Chengji Wang, Yuanzheng Liang, Xindi Liu, Lijie Zeng, Liang Wang","doi":"10.1080/10428194.2026.2712107","DOIUrl":"10.1080/10428194.2026.2712107","url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically heterogeneous malignancy, but the prognostic and biological significance of O-linked β-N-acetylglucosamine (O-GlcNAc) modification remains incompletely understood. We analyzed three microarray-based DLBCL cohorts obtained from the Gene Expression Omnibus (GSE87371, GSE117556, and GSE181063; total n = 2,090). Consensus clustering was used to characterize the expression patterns of glycosylation-related genes. The associations of these expression patterns and O-GlcNAc transferase (OGT) expression with overall survival were evaluated using Kaplan-Meier analysis and Cox regression. Differential expression, pathway enrichment, single-sample gene set enrichment, and correlation analyses were performed to characterize biological features associated with OGT expression. We also used OCI-LY3 and SU-DHL-4 cell lines to investigate the effects of OGT overexpression, shRNA-mediated knockdown, and pharmacological inhibition on cell proliferation and apoptosis. Co-immunoprecipitation and immunoblotting were performed to assess protein O-GlcNAcylation and phosphorylation, together with selected signaling proteins, anti-apoptotic factors, and epigenetic regulators. In result, Glycosylation-related genes displayed heterogeneous expression patterns across DLBCL samples that were associated with survival, with OGT emerging as a key prognostic candidate. High OGT expression was associated with shorter survival in all three cohorts, and patients with OGT overexpression and high International Prognostic Index scores had particularly poor outcomes. Increased levels of OGT expression co-varied with PI3K-AKT-MTOR signaling, MYC target signaling, and selected anti-apoptotic and epigenetic features. In both cell lines, OGT overexpression promoted proliferation and was accompanied by increased O-GlcNAcylation and activation-associated phosphorylation of PI3K, AKT, and Myc, together with increased protein levels of Bcl-2, Mcl-1, EZH2, and KMT2D. OGT knockdown or pharmacological inhibition produced opposite changes and increased apoptosis. These findings indicate that elevated OGT expression is associated with unfavorable survival and adverse signaling features in DLBCL. Further studies are required to establish the direct causal relationships and therapeutic significance of OGT-associated O-GlcNAcylation.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-26"},"PeriodicalIF":2.1,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148726507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additional myelodysplasia-related gene mutations alter clinical presentation and worsen prognosis in patients with <i>SRSF</i>/<i>TET2</i> co-mutated myeloid neoplasms.","authors":"Michael Martin, Samuel G Cockey, Veena Jajoo, Mac Shebes, Hailing Zhang, Le Wang, Lynn Moscinski, Julie Li, Emily Coughlin, Rahul Mhaskar, Jinming Song","doi":"10.1080/10428194.2026.2714598","DOIUrl":"10.1080/10428194.2026.2714598","url":null,"abstract":"<p><p><i>SRSF2/TET2</i> is a common co-mutation characterized by monocytosis across many myeloid neoplasms, including CMML. Myelodysplasia-related gene (MRG) mutations, including <i>SRSF2</i>, <i>SF3B1</i>, <i>U2AF1</i>, <i>ZRSR2</i>, <i>ASXL1</i>, <i>EZH2</i>, <i>BCOR</i>, and <i>STAG2</i>, are key contributors to leukemic transformation, though their interactions with other mutations are understudied. In this retrospective cohort study, we examined the clinical and prognostic impact of additional mutated MRGs in 412 patients with <i>SRSF2</i>/<i>TET2</i> co-mutated neoplasms, identified from the Moffitt Next Gen Sequencing Database. The majority of patients (55%) had at least one additional MRG mutation, which was associated with decreased monocytosis, increased anemia, and poorer overall survival (10.941 vs. 23.787 months, <i>p</i> < 0.001). <i>ASXL1</i> was the most common MRG mutation and independently predicted worse survival. Patients with additional MRGs were more likely to have AML arising from CMML (12.3% vs 5.9%, <i>p</i> = 0.029). These findings may be used in future clinical practice to provide better prognosis and treatment stratification.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148722929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.","authors":"Yotam Bronstein, Lior Rokach, Yair Herishanu, Ronen Arbel, Talish Razi, Noy Nachmias","doi":"10.1080/10428194.2026.2711592","DOIUrl":"https://doi.org/10.1080/10428194.2026.2711592","url":null,"abstract":"<p><p>Liver biochemical abnormalities are relatively common at chronic lymphocytic leukemia (CLL) diagnosis, but their prognostic significance is unclear. We conducted a nationwide real-world study of 3448 adults with newly diagnosed CLL in Clalit Health Services, Israel, with liver biochemistry assessed within ±3 months of diagnosis and no documented preexisting liver disease. Cholestatic elevation was defined as elevated alkaline phosphatase and/or gamma-glutamyl transferase; hepatocellular elevation as elevated alanine and/or aspartate aminotransferase. Median follow-up was 74.9 months. Cholestatic and hepatocellular elevations were present in 16.4% and 6.0% of patients, respectively. In multivariable Cox models, cholestatic elevation was independently associated with inferior overall survival (hazard ratio (HR), 1.21; 95% CI, 1.05-1.39; <i>p</i> = 0.008), whereas hepatocellular elevation did not. Neither pattern was independently associated with time to first treatment. Cholestatic elevation was also associated with increased infection-related hospitalization rates and hospitalized days, identifying a clinically vulnerable subgroup at CLL diagnosis.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2026-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.","authors":"Nikki Agarwal, Brenda W Cooper, Ben K Tomlinson, Michael Daunov, Pingfu Fu, Rebecca B Klisovic, Marcos de Lima, Folashade Otegbeye, Yeritza Hernandez-Collazo, Jignesh Dalal, Mari Dallas, Seunghee Margevicius, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny","doi":"10.1080/10428194.2026.2707893","DOIUrl":"https://doi.org/10.1080/10428194.2026.2707893","url":null,"abstract":"<p><p>We conducted a phase II study of fludarabine, thiotepa, reduced dose melphalan conditioning for allogeneic transplantation using alternate donors. Thirty-eight patients with hematological malignancies were enrolled. Conditioning included fludarabine 160 mg/m², thiotepa 10 mg/kg (dose adjusted to 5 mg/kg for age >60 years) and melphalan 100 mg/m². Sixteen patients (42%) received reduced intensity thiotepa (5 mg/kg). Twenty-one patients (55%) had acute myeloid leukemia, rest had acute lymphoblastic leukemia, myelodysplastic syndrome, myelofibrosis and relapsed high-risk lymphomas. Twenty-eight (74%) underwent haplo-identical transplants-rest received double cord blood grafts. With median follow up of 38 months, Day +100 marrow demonstrated morphologic complete remission in 34/38 evaluable patients. Progression-free survival at 1-, 2- and 3-year was 68%, 63% and 63%, respectively. Overall survival at 1-, 2- and 3-year was 76%, 71% and 64%, respectively. One-year non-relapse mortality was 21% and relapse rate was 11%. Twelve patients received post-transplant maintenance therapy. We conclude that fludarabine/thiotepa/low dose melphalan can induce durable long-term remissions in patients with advanced disease.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare.","authors":"Atinuke G Oyinbo, Maira A Castaneda-Avila, Jonggyu Baek, Mayra Tisminetzky, Muthalagu Ramanathan, Kate L Lapane, Mara M Epstein","doi":"10.1080/10428194.2026.2711165","DOIUrl":"https://doi.org/10.1080/10428194.2026.2711165","url":null,"abstract":"<p><p>This study examined the association between multimorbidity patterns and survival in patients with multiple myeloma (2007-2017) using SEER-Medicare (<i>n</i> = 7281). We determined survival differences between patients with low severity multimorbidity, concurrent psychiatric/musculoskeletal disorders, and concurrent cardiometabolic/multisystem impairments. Survival probabilities were compared between the pre- and post-novel drug era to account for the impact of novel therapies. The cardiometabolic/multisystem multimorbidity group had an increased risk of overall (adjusted hazard ratio (HR): 1.64, 95% confidence interval (CI): 1.53-1.77) and cancer-specific mortality (adjusted HR: 1.47, 95% CI: 1.32-1.63) than those with low severity multimorbidity. There were no differences in mortality risk between psychiatric/musculoskeletal and low severity multimorbidity patterns. Survival probabilities were more similar between multimorbidity patterns in the post-novel drug era. The findings suggest that older adults with an elevated multimorbidity burden at diagnosis with multiple myeloma have poor survival outcomes and necessitate the development of health interventions to improve their cancer prognosis.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of imatinib maintenance after stem cell transplantation for Ph+/<i>BCR</i>::<i>ABL1</i> positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.","authors":"Heike Pfeifer, Wolfgang Bethge, Stefan Schönland, Lisa Heberling, Leo Ruhnke, Michael Stadler, Dietrich Beelen, Vladan Vučinić, Thomas Burmeister, Matthias Stelljes, Christoph Faul, Alexander Kiani, Knut Wendelin, Rainer Schwerdtfeger, Elisabeth Lange, Boris Kubuschok, Heinz-August Horst, Martin Gramatzki, Hubert Serve, Dieter Hoelzer, Nicola Gökbuget, Oliver G Ottmann, Fabian Lang","doi":"10.1080/10428194.2026.2707442","DOIUrl":"10.1080/10428194.2026.2707442","url":null,"abstract":"<p><p>Tyrosine kinase inhibitors are recommended as maintenance therapy following allogeneic stem cell transplantation (HSCT) for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), but optimal medication, dose, and duration remain a subject of ongoing study. We provide the final analysis of a prospective randomized trial comparing prophylactic and minimal residual disease (MRD)-triggered imatinib maintenance. The two patient cohorts did not differ significantly in terms of cumulative incidence of relapse (CIR; 14% vs. 18%), non-relapse mortality (NRM; 12% vs. 11%), leukemia-free survival (LFS) 64% vs. 69%, and overall survival (OS) at 10 years (68% vs. 71%). Endpoints were assessed every 6 weeks within the trial from 4 weeks after SCT until EOS at week 55 and after that according to local standards. In summary, this provides a framework for MRD-based treatment of patients for maintenance after HSCT with excellent long-term outcome after 10 years in both groups.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytarabine as a salvage mobilization strategy after failure of cyclophosphamide-based stem cell collection for Daratumumab-treated multiple myeloma patients.","authors":"Tommaso Perini, Alessia Orsini, Francesca Farina, Valeria Ferla, Raffaella Milani, Sarah Marktel, Luca Canziani, Rossella Gammino, Daniele Sannipoli, Filippo Magri, Rosamaria Nitti, Milena Coppola, Sara Mastaglio, Magda Marcatti, Fabio Ciceri","doi":"10.1080/10428194.2026.2666848","DOIUrl":"10.1080/10428194.2026.2666848","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1986-1989"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}